Press Release
Communiqué de presse
–
October 03, 2024
3 October, 2024
Sernova to Present at the 2024 Cell & Gene Meeting on the Mesa
LONDON, Ontario; BOSTON, Massachusetts – October 3, 2024 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF)
(FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative
medicine cell therapies for treatment of chronic diseases, announced that its CEO, Jonathan Rigby, will be
presenting at the 2024 Cell & Gene Meeting on the Mesa being held October 7-9, 2024, at the Arizona Biltmore
Hotel in Phoenix, Arizona. The Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference
bringing together senior executives and top decision-makers in the industry to advance cutting-edge research
into cell therapy cures.
Mr. Rigby’s presentation is scheduled to begin at 10:00 A.M. MT (12:00 P.M. ET) on Monday, October 7, 2024.
The presentation will include updates on Sernova’s type 1 diabetes phase 1/2 clinical trial at the University of
Chicago, and its pre-clinical work with Evotec to advance a potential iPSC-based (induced pluripotent stem cell)
islet replacement therapy with Sernova’s Cell Pouch™ Transplant System.
ABOUT SERNOVA AND ITS CELL POUCH™ TRANSLPLANT SYSTEM PLATFORM FOR CELL THERAPY
Sernova Corp. is a clinical-stage biotechnology company that is developing therapeutic cell technologies for
chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include
hemophilia A. Sernova is currently focused on developing a ‘functional cure’ for insulin-dependent diabetes with
its lead technology, the Cell Pouch Transplant System, a novel implantable and scalable medical device with
immune protected therapeutic cells.
On implantation, The Cell Pouch forms a natural, vascularized tissue environment in the body allowing long-term
survival and function of therapeutic cells that release essential factors that are absent or deficient in patients with
certain chronic diseases. Sernova’s Cell Pouch Transplant System has demonstrated its potential to be a
‘functional cure’ for people with T1D in an ongoing Phase I/II clinical study at the University of Chicago.
Sernova partnered with Evotec to develop an implantable off-the-shelf iPSC (induced pluripotent stem cells)
based islet replacement therapy. This partnership provides Sernova a potentially unlimited supply of insulin-
producing cells to treat millions of patients with insulin-dependent diabetes (type 1 and type 2). Sernova’s
development pipeline that uses its Cell Pouch Transplant System also includes: a cell therapy for hypothyroid
disease resulting from thyroid gland removal and an ex vivo lentiviral Factor VIII gene therapy for hemophilia A.
FOR FURTHER INFORMATION, PLEASE CONTACT:
David Burke
VP, Investor Relations
Sernova Corp.
Tel: +1 917-618-2651
Email: david.burke@sernova.com
Website: www.sernova.com
The TSX has not reviewed this news release and does not accept responsibility for the accuracy or adequacy of
this news release.
FORWARD-LOOKING INFORMATION
This release contains statements that, to the extent they are not recitations of historical facts, may constitute
“forward-looking statements” that involve various risks, uncertainties, and assumptions, including, without
limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but not
always, words such as “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential
for” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur are
used to identify forward-looking statements. These statements reflect management’s beliefs with respect to
future events and are based on information currently available to management on the date such statements were
made. Many factors could cause Sernova’s actual results, performances or achievements to not be as
anticipated, estimated or intended or to differ materially from those expressed or implied by the forward-looking
statements contained in this news release. Such factors could include, but are not limited to, the company’s
ability to secure additional financing and licensing arrangements on reasonable terms, or at all; ability to conduct
all required preclinical and clinical studies for the company’s Cell Pouch System and or related technologies,
including the timing and results of those trials; ability to obtain all necessary regulatory approvals, or on a timely
basis; ability to in-license additional complementary technologies; ability to execute its business strategy and
successfully compete in the market; and the inherent risks associated with the development of biotechnology
combination products generally. Many of the factors are beyond our control, including those caused by, related
to, or impacted by the novel coronavirus pandemic. Investors should consult the company’s quarterly and annual
filings available on www.sedarplus.ca for additional information on risks and uncertainties relating to the
forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information, future events or otherwise.